Inside FDA’s Debates On ‘Breakthrough’
Office of New Drugs Director Jenkins provides a peek into the Medical Policy Council’s efforts to consistently interpret and implement the ‘breakthrough therapy’ program.
Office of New Drugs Director Jenkins provides a peek into the Medical Policy Council’s efforts to consistently interpret and implement the ‘breakthrough therapy’ program.